FDA Approved: OXYTROL — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for OXYTROL (oxybutynin) filed by Allergan, Inc. This decision updates the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurogenic Bladder
• Overactive Bladder
• Urinary Incontinence

Drugs mentioned

• OXYTROL (OXYBUTYNIN)

Snippet

SUPPL AP for OXYTROL (OXYBUTYNIN)